Background: Patients treated with ticlopidine require careful hematologic monitoring. Clopidogrel may have greater tolerability. However, no direct comparison of these two drugs has been reported and evidence of improved safety with clopidogrel is not yet established in the Japanese population. A comparison of both agents was therefore conducted in Japanese stroke patients. Methods: Patients with noncardioembolic cerebral infarction were randomized to clopidogrel 75 mg or ticlopidine 200 mg once daily for 52 weeks. The primary endpoint was safety; the major secondary endpoint was the incidence of vascular events.Results: Clopidogrel was associated with significantly fewer safety events than ticlopidine (7.0 versus 15.1%; p < 0.001) and no significant difference in efficacy between the two treatments was seen [hazard ratio 0.977 (95% confidence interval: 0.488–1.957)].Conclusions: In Japanese stroke patients, clopidogrel 75 mg is better tolerated than ticlopidine 200 mg once daily.

Keywords:
Clopidogrel, Ticlopidine, Ischemic stroke
1.
Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community. The Hisayama Study. Stroke 2003;34:2349–2354.
2.
Statistics and Information Department, Ministry of Health, Labour and Welfare, Japanese Government: Abridged Life Tables for Japan 2005. www.mhlw.go.jp. Last accessed November 10, 2006.
3.
Hier DB, Foulkes MA, Swiontoniowski M, Sacco RL, Gorelick PB, Mohr JP, Price TR, Wolf PA: Stroke recurrence within 2 years after ischemic infarction. Stroke 1991;22:155–161.
4.
Uchiyama S, Nakamura T, Yamazaki M, Kimura Y, Iwata M: New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis 2006;21(suppl 1):7–16.
5.
The Joint Committee on Guidelines for the Management of Stroke: Japanese Guidelines for the Management of Stroke (in Japanese). Tokyo, Kyowa Kikaku, 2004.
6.
Shinohara Y: Regional differences in incidence and management of stroke – is there any difference between Western and Japanese guidelines on antiplatelet therapy? Cerebrovasc Dis 2006;21(suppl 1):17–24.
7.
Yamazaki T, Goto S, Shigematsu H, Shimada K, Uchiyama S, Nagai R, Yamada N, Matsumoto M, Origasa H, Ikeda Y; REACH Registry Investigators: Prevalence, awareness, and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J 2007;71:995–1003.
8.
Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501–507.
9.
Caplan LR: Antiplatelet therapy in stroke prevention: present and future. Cerebrovasc Dis 2006;21(suppl 1):1–6.
10.
Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD: Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999;159:2524–2528.
11.
CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–1339.
12.
Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, Shimizu S, Masumoto H, Okutani Y: Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2007, Epub ahead of print, DOI:10.1038/sj.tpj.6500442.
13.
Harker LA, Boissel JP, Pilgrim AJ, Gent M, on behalf of the CAPRIE Steering Committee and Investigators: comparative safety and tolerability of clopidogrel and aspirin. Drug Saf 1999;21:325–335.
14.
Zakarija A, Bandarenko N, Pandey DK, Auerbach A, Raisch DW, Kim B, Kwaan HC, McKoy JM, Schmitt BP, Davidson CJ, Yarnold PR, Gorelick PB, Bennett CL: Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004;35:533–537.
15.
Plavix (Sanofi-Aventis Bristol-Myers Squibb SNC), Summary of Product Characteristics. http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc.asp&documentid=9484. Last accessed January 16, 2007.
16.
Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai HM: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773–1777.
17.
Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y: Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147–157.
18.
Bezerra DC, Bogousslavsky J: Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives. Cerebrovasc Dis 2005;20(suppl 2):109–118.
19.
Tanahashi N: Treatment of acute-stage lacunar infarction and prevention of recurrence. Jpn J Stroke 1995;17:571–577.
20.
Steg PG, Bhatt DL, Wilson PW, D’Agostino R Sr, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators: One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197–1206.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.